Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $8.50 Consensus Price Target from Brokerages

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) has earned a consensus recommendation of “Hold” from the seven analysts that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $8.50.

AUTL has been the subject of several research analyst reports. Zacks Research lowered Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, January 21st. HC Wainwright assumed coverage on Autolus Therapeutics in a report on Tuesday, February 17th. They set a “buy” rating and a $9.00 target price on the stock. Needham & Company LLC dropped their price target on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, January 12th. Wall Street Zen downgraded shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, November 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a research report on Wednesday, January 21st.

Autolus Therapeutics Price Performance

AUTL opened at $1.51 on Wednesday. The business has a 50 day moving average price of $1.58 and a two-hundred day moving average price of $1.53. The company has a market capitalization of $401.87 million, a price-to-earnings ratio of -1.82 and a beta of 1.95. Autolus Therapeutics has a 1-year low of $1.11 and a 1-year high of $2.70.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Independent Advisor Alliance acquired a new stake in shares of Autolus Therapeutics during the 4th quarter valued at $28,000. Marex Group plc acquired a new position in shares of Autolus Therapeutics in the 2nd quarter worth $28,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Autolus Therapeutics during the fourth quarter worth $43,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Autolus Therapeutics during the third quarter valued at $46,000. Finally, R Squared Ltd lifted its holdings in shares of Autolus Therapeutics by 40.1% during the third quarter. R Squared Ltd now owns 30,476 shares of the company’s stock valued at $50,000 after purchasing an additional 8,730 shares during the last quarter. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.